JP2016517883A - Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 - Google Patents

Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 Download PDF

Info

Publication number
JP2016517883A
JP2016517883A JP2016511718A JP2016511718A JP2016517883A JP 2016517883 A JP2016517883 A JP 2016517883A JP 2016511718 A JP2016511718 A JP 2016511718A JP 2016511718 A JP2016511718 A JP 2016511718A JP 2016517883 A JP2016517883 A JP 2016517883A
Authority
JP
Japan
Prior art keywords
day
ald
vlcfa
dose
mcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016511718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517883A5 (enExample
Inventor
トーマス エス． スカンラン，
トーマス エス． スカンラン，
メレディス ハートレー，
メレディス ハートレー，
アンドリュー プラチェク，
アンドリュー プラチェク，
マルコ リギ，
マルコ リギ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Publication of JP2016517883A publication Critical patent/JP2016517883A/ja
Publication of JP2016517883A5 publication Critical patent/JP2016517883A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2016511718A 2013-05-03 2013-08-05 Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 Withdrawn JP2016517883A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018137754A Division JP2018162321A (ja) 2013-05-03 2018-07-23 Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Publications (2)

Publication Number Publication Date
JP2016517883A true JP2016517883A (ja) 2016-06-20
JP2016517883A5 JP2016517883A5 (enExample) 2016-09-23

Family

ID=51843844

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016511718A Withdrawn JP2016517883A (ja) 2013-05-03 2013-08-05 Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2016511726A Active JP6360552B6 (ja) 2013-05-03 2014-02-05 髄鞘形成疾患の処置におけるソベチロム
JP2018118891A Pending JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム
JP2018137754A Pending JP2018162321A (ja) 2013-05-03 2018-07-23 Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016511726A Active JP6360552B6 (ja) 2013-05-03 2014-02-05 髄鞘形成疾患の処置におけるソベチロム
JP2018118891A Pending JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム
JP2018137754A Pending JP2018162321A (ja) 2013-05-03 2018-07-23 Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Country Status (12)

Country Link
US (3) US10226438B2 (enExample)
EP (1) EP2991670B8 (enExample)
JP (4) JP2016517883A (enExample)
CN (1) CN105431163A (enExample)
AU (1) AU2014260468A1 (enExample)
BR (1) BR112015027682A2 (enExample)
CA (1) CA2911309A1 (enExample)
ES (1) ES2745532T3 (enExample)
MX (2) MX379043B (enExample)
RU (1) RU2015151216A (enExample)
SG (2) SG10201709090UA (enExample)
WO (2) WO2014178892A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500989A (ja) * 2019-12-31 2023-01-17 キロノヴァ （シアメン） バイオファーマ カンパニー リミテッド 甲状腺ホルモン受容体アゴニスト特性を有する肝臓標的化合物及びその医薬組成物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN108430514B (zh) * 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
CN109641003A (zh) * 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
EP3644983B1 (en) 2017-06-29 2023-10-25 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US11633433B2 (en) 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513461A (ja) * 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
JP2016517884A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー 髄鞘形成疾患の処置におけるソベチロム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
JP2002519340A (ja) 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) * 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
WO2014063720A1 (en) * 2012-10-25 2014-05-01 Renault Trucks Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513461A (ja) * 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
JP2016517884A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー 髄鞘形成疾患の処置におけるソベチロム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＳＴＥＲＯＩＤ ＢＩＯＣＨＥＭＩＳＴＲＹ ＆ ＭＯＬＥＣＵＬＡＲ ＢＩＯＬＯＧ, vol. Ｖｏｌｕｍｅ １１６、Ｉｓｓｕｓ １−２, JPN6017016645, 2009, pages 37 - 43, ISSN: 0003555075 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500989A (ja) * 2019-12-31 2023-01-17 キロノヴァ （シアメン） バイオファーマ カンパニー リミテッド 甲状腺ホルモン受容体アゴニスト特性を有する肝臓標的化合物及びその医薬組成物
JP7265817B2 (ja) 2019-12-31 2023-04-27 キロノヴァ （シアメン） バイオファーマ カンパニー リミテッド 甲状腺ホルモン受容体アゴニスト特性を有する肝臓標的化合物及びその医薬組成物

Also Published As

Publication number Publication date
WO2014178892A1 (en) 2014-11-06
MX379043B (es) 2025-03-10
JP6360552B6 (ja) 2018-08-15
JP6360552B2 (ja) 2018-07-18
SG10201709090UA (en) 2017-12-28
EP2991670B8 (en) 2019-09-11
EP2991670A1 (en) 2016-03-09
WO2014178931A8 (en) 2015-11-26
MX2021000538A (es) 2021-04-28
WO2014178892A8 (en) 2015-12-17
BR112015027682A2 (pt) 2017-08-29
SG11201509012QA (en) 2015-11-27
AU2014260468A1 (en) 2015-11-19
CN105431163A (zh) 2016-03-23
US11510887B2 (en) 2022-11-29
US20160081955A1 (en) 2016-03-24
JP2018141024A (ja) 2018-09-13
US20200405669A1 (en) 2020-12-31
WO2014178931A1 (en) 2014-11-06
RU2015151216A (ru) 2017-06-08
US10226438B2 (en) 2019-03-12
CA2911309A1 (en) 2014-11-06
MX2015015228A (es) 2016-10-03
JP2018162321A (ja) 2018-10-18
EP2991670A4 (en) 2017-01-18
HK1222552A1 (en) 2017-07-07
EP2991670B1 (en) 2019-07-03
ES2745532T3 (es) 2020-03-02
JP2016517884A (ja) 2016-06-20
US20190175531A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JP2018162321A (ja) Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
Kwak et al. Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia
RU2746000C2 (ru) Состав для ингибирования образования агонистов 5-ht2b и способы его применения
Rossi et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels
Wu et al. Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity
CN110087684B (zh) 用于治疗肥胖及相关病症的肌肉生长抑制素、激活素或激活素受体拮抗剂
Nolan Metabolic complications associated with HIV protease inhibitor therapy
De Boer et al. Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease
Tazi et al. Treatment of cachexia in oncology
Mantovani et al. Cancer cachexia: medical management
WO2021126320A1 (en) Treatment of amyotrophic lateral sclerosis
CN110891558A (zh) 使用芬氟拉明治疗多泽综合征的方法
Romualdi et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial
Macha et al. Lack of clinically relevant drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers
JP7749593B2 (ja) 褐色脂肪生成を誘導する方法及び組成物
KR20180121983A (ko) Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
KR20220110731A (ko) 치매에서의 glp-1 수용체 작용제
Lapuerta et al. Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
JP2025031720A (ja) カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物
Zhang et al. Tetrandrine attenuates SNI-induced mechanical allodynia by inhibiting spinal CKLF1
EP3930711A2 (en) Materials and methods for treating a neurodegenerative disease
KR20190065252A (ko) 골 질환 치료용 PPARγ 작용제
Jo et al. Synergistic effects of C–C chemokine receptor 2 inhibitor and transforming growth factor-β type I receptor kinase inhibitor combination in metabolic dysfunction-associated steatohepatitis
Gerrits et al. Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20160105

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180326

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180821